Screening the Effectiveness of Kabasura Kudineer against COVID 19 and
Immune Proteins in Humans: In silico

Architha      Vijayalakshmi; Hemalatha      Srinivasan

Abstract

Background: The advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first century. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has greatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants. However, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and their side effects.

Objective: The main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against COVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans.

Methods: The molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check the Pharmacokinetics.

Results: The results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.

Conclusion: Siddha way of treatment has popped out which has been traditionally used for the treatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven to have antiviral agents and compounds that boost the immune system.

Graphical Abstract

[1]
Miyah Y, Benjelloun M, Lairini S, Lahrichi A. COVID-19 impact on public health, environment, human psychology, global socioeconomy, and education. Sci World J  2022; 2022

[2]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med  2020; 8(4): 420-2.
 [http://dx.doi.org/10.1016/S2213-2600(20)30076-X]

[3]
Noor AU, Maqbool F, Bhatti ZA, Khan AU. Epidemiology of CoViD-19 Pandemic: Recovery and mortality ratio around the globe. Pakistan J Med Sci  2020; 36: 79.

[4]
Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: A brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res  2020; 21(1): 224.
 [http://dx.doi.org/10.1186/s12931-020-01479-w]

[5]
De Wit E, Van Doremalen N, Falzarano D. SARS MERS Recent insights into Emerg coronaviruses. Nat Rev Microbiol  2016; 14(8): 523-34.

[6]
Hebbani AV, Pulakuntla S, Pannuru P, Aramgam S, Badri KR, Reddy VD. COVID-19: Comprehensive review on mutations and current vaccines. Arch Microbiol  2022; 204(1): 8.
 [http://dx.doi.org/10.1007/s00203-021-02606-x]

[7]
Abo-zeid Y, Ismail NSM, McLean GR, Hamdy NM. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. Eur J Pharm Sci  2020; 153: 105465.
 [http://dx.doi.org/10.1016/j.ejps.2020.105465]

[8]
Kong R, Yang G, Xue R, et al. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. Bioinformatics  2020; 36(20): 5109-11.
 [http://dx.doi.org/10.1093/bioinformatics/btaa645]

[9]
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res  2020; 288: 198114.
 [http://dx.doi.org/10.1016/j.virusres.2020.198114]

[10]
Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: Findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med  2023; 11(5): 439-52.
 [http://dx.doi.org/10.1016/S2213-2600(23)00015-2]

[11]
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses drug discovery and therapeutic options. Nat Rev Drug Discov  2016; 15(5): 327-47.
 [http://dx.doi.org/10.1038/nrd.2015.37]

[12]
Harini P, Veeraraghavan VP, Selvaraj J, Gayathri R, Kavitha S. Antidiabetic activity of Kabasura Kudineer Chooranam. J Adv Pharm Technol Res  2022; 13 (Suppl. 2): S383-6.

[13]
Jain J, Pai S, Sunil S. Standardization of in vitro assays to evaluate the activity of polyherbal siddha formulations against Chikungunya virus infection. Virusdisease  2018; 29(1): 32-9.
 [http://dx.doi.org/10.1007/s13337-018-0421-0]

[14]
Jain J, Narayanan V, Chaturvedi S, Pai S, Sunil S. In vivo evaluation of withania somnifera–based Indian traditional formulation (Amukkara choornam), against chikungunya virus–induced morbidity and arthralgia. J Evid Based Integr Med  2018; 23.
 [http://dx.doi.org/10.1177/2156587218757661]

[15]
Chaskar AC. Antioxidative potential of Kabasura Kudineer (KSK), an official Siddha polyherbal formulation. Int J Pharm Res  2021; 13(2)

[16]
Selvam P, Illanjiam S, Ramesh T, Aravindh R, Vasanthraj R. Investigation of anticancer and antimicrobial activities of Kabasura Kudineer: A polyherbal formulation. Evid Based Herb Med 

[17]
Aromal SS, Chaly PE. Assessment of antimicrobial efficacy of kabasura kudineer choornam against common oral microbes-a randomised in vitro study on biofilm model. J Pharm Negat Results  2022; 2004-12.

[18]
Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials  2021; 22(1): 623.
 [http://dx.doi.org/10.1186/s13063-021-05583-0]

[19]
Bala D. Attitudes, beliefs, and self-use of Kabasura Kudineer among urban and rural population in Tamil Nadu, India: A comparative cross-sectional study. J Fam Med Prim Care  2021; 10(1): 158.

[20]
Khapre M, Pathania M, Saxena V, et al. Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial. J Ayurveda Integr Med  2023; 14(4): 100777.
 [http://dx.doi.org/10.1016/j.jaim.2023.100777]

[21]
Kabilan SJ, Kunjiappan S, Sundaresan H, Mahesh S, Srinivasan G. Therapeutic efficacy of polyherbal formulation kabasura kudineer against common viral fevers-a perspective review. Antiinfect Agents  2022; 20(5): e270522205330.
 [http://dx.doi.org/10.2174/2211352520666220527102858]

[22]
Arivarasan VK. In vitro Immunomodulatory activity and Thrombolytic potential of Kabasura Kudineer (KSK), an official Siddha polyherbal formulation. 2020.

[23]
Shukla S, Rehman MU, Tiwari R, Shukla M, Kalaiselvan V, Kandadamy E. Physicochemical characterization and HPTLC profiling of commercially available Kabasura Kudineer Chooranam. Indian J Tradit Knowl  2021; 20(3): 629-37.

[24]
Srivastava A, Rengaraju M, Srivastava S, et al. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients—a double-blind, placebo-controlled, clinical trial. Trials  2021; 22(1): 570.
 [http://dx.doi.org/10.1186/s13063-021-05478-0]

[25]
Mekala P, Murthy TRGK. Phytochemical screening and pharmacological update on Kabasura Kudineer choornam and Nilavembu Kudineer Choornam. J Pharmacogn Phytochem  2020; 9(3): 1031-6.
 [http://dx.doi.org/10.22271/phyto.2020.v9.i3q.11428]

[26]
Yessu AM. Evaluation of toxicity profiles of siddha preparation of ‘kabasura kudineer’in laboratory animals. World J Pharm Sci  2020; 14-8.

[27]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA  2020; 323(11): 1061-9.

[28]
Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect  2020; 80(6): 656-65.
 [http://dx.doi.org/10.1016/j.jinf.2020.03.041]

[29]
Akbari H, Tabrizi R, Lankarani KB, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Life Sci  2020; 258: 118167.
 [http://dx.doi.org/10.1016/j.lfs.2020.118167]

[30]
Yang Y, Shen C, Li J, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol  2020; 146(1): 119-127.e4.
 [http://dx.doi.org/10.1016/j.jaci.2020.04.027]

[31]
Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol  2020; 92(4): 424-32.
 [http://dx.doi.org/10.1002/jmv.25685]

[32]
George M. Hemophagocytic lymphohistiocytosis: Review of etiologies and management. J Blood Med  2014; 69-86.
 [http://dx.doi.org/10.2147/JBM.S46255]

[33]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet  2020; 395(10223): 497-506.
 [http://dx.doi.org/10.1016/S0140-6736(20)30183-5]

[34]
Basha SS, Tripathi D, Koora S, Satyanarayana K, Jayaraman S. Molecular docking analysis of potential compounds from an Indian medicinal soup “kabasura kudineer” extract with IL-6. Bioinformation  2021; 17(5): 568-672.
 [http://dx.doi.org/10.6026/97320630017568]

[35]
VR V. Interleukin-10 as COVID-19 biomarker targeting KSK and its analogues: Integrated network pharmacology. PLoS One  2023; 18(3): e0282263.
 [http://dx.doi.org/10.1371/journal.pone.0282263]

[36]
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. In: Seminars in immunopathology.  Springer 2017; pp. 529-39.
 [http://dx.doi.org/10.1007/s00281-017-0629-x]

[37]
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. Chloroquine is a potent Inhib SARS coronavirus Infect spread. J Virol  2005; 2: 69.

[38]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci  2020; 117(20): 10970-5.
 [http://dx.doi.org/10.1073/pnas.2005615117]

[39]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents  2020; 56(1): 105949.
 [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]

[40]
Bizzarri M, Laganà AS, Aragona D, Unfer V. Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2? Eur Rev Med Pharmacol Sci  2020; 24(6)

[41]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res  2020; 30(3): 269-71.
 [http://dx.doi.org/10.1038/s41422-020-0282-0]

[42]
Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci  2020; 250: 117583.
 [http://dx.doi.org/10.1016/j.lfs.2020.117583]

[43]
Jayaraj JM, Jothimani M, Palanisamy CP, et al. Computational study on the inhibitory effect of natural compounds against the SARS-CoV-2 proteins. Bioinorg Chem Appl  2022; 2022: 1-19.
 [http://dx.doi.org/10.1155/2022/8635054]

[44]
Shaik S, Soundhararajan R, Srinivasan H. Repurposing of drugs targeted against COVID-19 spike receptor for treatment: An in silico approach. Biointerface Res Appl Chem  2021; 11(5): 13740-53.
 [http://dx.doi.org/10.33263/BRIAC115.1374013753]

[45]
Jose SP, Ratheesh M, Sheetal S, et al. Anti-inflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A Siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells. J Ethnopharmacol  2022; 283: 114738.
 [http://dx.doi.org/10.1016/j.jep.2021.114738]

[46]
Vincent S, Arokiyaraj S, Saravanan M, Dhanraj M. Molecular docking studies on the anti-viral effects of compounds from Kabasura Kudineer on SARS-CoV-2 3CLpro. Front Mol Biosci  2020; 7: 613401.
 [http://dx.doi.org/10.3389/fmolb.2020.613401]

[47]
Ortega SS, Cara LCL, Salvador MK. In silico pharmacology for a multidisciplinary drug discovery process. dmdi  2012; 27(4): 199-207.
 [http://dx.doi.org/10.1515/dmdi-2012-0021]

[48]
Kiran G, Karthik L, Shree Devi MS, et al. In silico computational screening of Kabasura Kudineer - Official Siddha Formulation and Jacom against SARS-CoV-2 spike protein. J Ayurveda Integr Med  2022; 13(1): 100324.
 [http://dx.doi.org/10.1016/j.jaim.2020.05.009]

[49]
Kumar MP, Sundaram KM, Ramasamy MS. Coronavirus spike (S) glycoprotein (2019-ncov) targeted siddha medicines Kaba Sura Kudineer and Thontha Sura Kudineer–In silico evidence for corona viral drug. Asian J Pharmaceut Res Health Care  2020; 12(1): 20-7.
 [http://dx.doi.org/10.18311/ajprhc/2020/25103]

[50]
DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsl Protein Crystall  2002; 40(1): 82-92.

[51]
Gil C, Ginex T, Maestro I, et al. COVID-19: Drug targets and potential treatments. J Med Chem  2020; 63(21): 12359-86.
 [http://dx.doi.org/10.1021/acs.jmedchem.0c00606]

[52]
Habtemariam S, Nabavi SF, Banach M, et al. Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy? Arch Med Res  2020; 51(7): 733-5.
 [http://dx.doi.org/10.1016/j.arcmed.2020.05.024]

[53]
Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol  2020; 17(6): 613-20.
 [http://dx.doi.org/10.1038/s41423-020-0400-4]

Cite As

Coronaviruses

Screening the Effectiveness of Kabasura Kudineer against COVID 19 and Immune Proteins in Humans: In silico

Abstract

Graphical Abstract